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STATE-OF-THE-ART REVIEW

COVID-19 Clinical Trials
A Primer for the Cardiovascular and Cardio-Oncology
Communities
Bonnie Ky, MD, MSCE,a,b Douglas L. Mann, MDc

ABSTRACT
The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the
spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used
to treat patients with COVID-19 are repurposed treatments for inﬂuenza, Ebola, or for malaria that were developed
decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, we provide a
foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19,
so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical
trials that are ongoing for the treatment of patients with COVID-19. (J Am Coll Cardiol CardioOnc 2020;2:254–69)
© 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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HIGHLIGHTS
 SARS-CoV-2, the virus that causes
COVID-19, is a novel CoV that infects
humans by binding to ACE2, which degrades angiotensin II, and hence plays a
critical role in modulating the renin
angiotensin system (RAS).
 The emerging epidemiology of COVID-19
suggests that patients with cardiovascular risk factors, including older age, cardiovascular disease, or cancer may be
more susceptible to infection and suffer
from worse clinical outcomes.
 Because of the limited understanding
with respect to the interaction of RAS
inhibitors and SARS-CoV-2 infectivity, we
endorse current society recommendations to continue RAS antagonists for
clinical indications for which these
agents are known to be beneﬁcial.
 Treatments for COVID-19 that are undergoing clinical trials range from therapies that block the entry of SARS-CoV-2
into host cells, to repurposed antiviral
therapies such as protease inhibitors and
nucleoside analogs that block viral
replication by inhibiting viral RNAdependent RNA polymerase.
into the disease (3). In this multicenter retrospective
analysis, the majority were Wuhan residents or had
contact with Wuhan residents, although 25.9% were
neither. The median age of patients was 47 years
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infection and suffer from worse clinical out-

ABBREVIATIONS

comes (4). COVID-19 can also directly result

AND ACRONYMS

in a number of cardiovascular complications,
including fulminant myocarditis, myocardial
injury, heart failure, and arrhythmia (3,5,6).

ACE = angiotensin-converting
enzyme

AT1R = angiotensin II type 1

There have been a number of published case

receptor

reports of clinically suspected myocarditis as

CI = conﬁdence interval

suggested by: markedly elevated troponin
levels, ST-segment elevation on electrocardiogram without obstructive coronary dis-

CoV = coronavirus
COVID-19 = coronavirus
disease-2019

ease, severely decreased left ventricular

FDA = Food and Drug

systolic function, and shock (7), with cardiac

Administration

magnetic resonance imaging evidence of

IFN = interferon

diffuse myocardial edema and gadolinium

IL = interleukin

enhancement (8). However, in another iso-

IQR = interquartile range

lated autopsy report from a patient who suffered from SARS-CoV-2–related pneumonia

MERS = Middle East
respiratory syndrome

and cardiac arrest, no obvious histological

RAS = renin-angiotensin

changes in the myocardium were observed

system

with the exception of few interstitial mono-

RNA = ribonucleic acid

nuclear inﬂammatory inﬁltrates (9).
Elevated troponin levels have also been
observed in those with worse clinical outcomes.

In

a

retrospective,

single-center

analysis of 416 hospitalized patients with
conﬁrmed COVID-19, 19.7% displayed evi-

sACE2 = soluble angiotensinconverting enzyme 2

SARS-CoV-2 = severe acute
respiratory syndromecoronavirus-2

TMPRSS2 = transmembrane
protease serine 2

dence of cardiac injury, as deﬁned by
elevated high-sensitivity troponin I levels greater
than the 99th percentile upper limit. Those with
conﬁrmed cardiac injury tended to be older (median
age of 74 vs. 60 years) and suffer from hypertension
(59.8% vs. 23.4%), diabetes (24.4% vs. 12.0%), coronary heart disease (29.3% vs. 6.0%), heart failure
(14.6% vs. 1.5%), or cancer (8.5% vs. 0.6%) (10).
COVID-19 IN PATIENTS WITH CARDIOVASCULAR

(interquartile range [IQR]: 35 to 58 years), and 41.9%

RISK FACTORS OR DISEASE. Patients with cardio-

were female. Patients with more severe disease,

vascular risk factors or disease are at increased risk of

compared with those with nonsevere disease, tended

suffering from worse clinical outcomes with COVID-

to be older and tended to suffer from at least 1 co-

19. In an analysis of 2 cohorts from Jinyintan Hospi-

morbidity. In this retrospective analysis, patients

tal and Wuhan Hospital of 191 patients, patients with

commonly received intravenous antibiotics (58.0%).

hypertension, diabetes, or coronary heart disease

Oseltamivir was administered in 35.8%, systemic

were at increased risk of in-hospital mortality (11).

steroids in 18.6%, and oxygen in 41.3% of patients.

The prevalence of hypertension among nonsurvivors

The median duration of hospitalization was 12.0 days

was 48% as compared to 30% in survivors; 31% versus

(IQR: 10.0 to 14.0 days); however, the majority of the

19% for diabetes, and 13% versus 8% for cardiovas-

patients (93.6%) remained hospitalized at the time of

cular disease. These comorbidities were also more

data analysis and as such, the clinical course still

likely to be present in patients who required intensive

largely remains to be deﬁned.

care unit admission (4). Other studies, including a
recently published meta-analysis of 46,248 infected

COVID-19 AND CARDIOVASCULAR COMPLICATIONS.

patients, have corroborated the observation that pa-

Epidemiologic data thus far suggest that patients with

tients with cardiovascular risk factors or cardiovas-

cardiovascular risk factors, including older age, car-

cular disease have worse clinical outcomes (12) and

diovascular disease, or cancer are more susceptible to

also suggest that hypertension (17  7%; 95%
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C E N T R A L IL L U ST R A T I O N SARS-CoV-2 Structure and Entry Into Cells

Ky, B. et al. J Am Coll Cardiol CardioOnc. 2020;2(2):254–69.

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus genome encodes 4 major structural proteins: the spike (S) protein;
the nucleocapsid (N) protein; the membrane (M) protein; and the envelope (E) protein. The S protein is responsible for facilitating entry of the
CoV into the target cell. The routes employed by SARS-CoV include endocytosis and membrane fusion. The route employed by SARS-CoV-2
is via endocytosis; whether SARS-CoV-2 enters cells by membrane fusion is not known. Binding of the S protein of SARS-CoV to angiotensinconverting enzyme 2 (ACE2) leads to the uptake of the virions into endosomes, where the viral S protein is activated by the pH-dependent
cysteine protease cathepsin L. Activation of the S protein by cathepsin L can be blocked by baﬁlomycin A1 and ammonium chloride, which
indirectly inhibit the activity of cathepsin L by interfering with endosomal acidiﬁcation. Chloroquine and hydroxychloroquine are weak bases
that diffuse into acidic cytoplasmic vesicles such as endosomes, lysosomes, or Golgi vesicles and thereby increases their pH. MDL28170
inhibits calpain and cathepsin L. SARS-CoV can also directly fuse with host cell membranes, after processing of the virus spike protein by
transmembrane protease serine 2 (TMPRSS2), a type II cell membrane serine protease. Camostat mesylate is an orally active serine protease
inhibitor. Modiﬁed from Simmons et al. (25). RNA ¼ ribonucleic acid.

conﬁdence interval [CI]: 14% to 22%), diabetes (8 

importantly 96.6% undertook quarantine procedures,

6%; 95% CI: 6% to 11%), and cardiovascular disease (5

did not suggest a markedly elevated rate of SARS-

 4%; 95% CI: 4% to 7%) were prevalent comorbid-

CoV-2 infection in this population (13,14).

ities among infected patients. Recent studies have

COVID-19 IN PATIENTS WITH CANCER. In a retro-

also demonstrated that age and hypertension were

spective medical review of 1,524 patients with cancer

predictors of an increased likelihood of cardiovascu-

who were admitted to the Department of Radiation

lar complications, and cardiovascular complications

and Medical Oncology in Zhongnan Hospital of

were associated with a 4.26-fold increased risk of

Wuhan University from December 30, 2019, to

death (95% CI: 1.9 to 9.49) (10).
COVID-19

IN

PATIENTS

WITH

February 17, 2020, the infection rate of SARS-CoV-2 in
HEART

TRANS-

patients with cancer was 0.79% (95% CI: 0.3% to 1.2%)

PLANTATION. There have been case series published

(15). In contrast, the estimated cumulative incidence

on COVID-19 infection in heart transplant recipients.

of all COVID-19 cases in Wuhan was 0.37%. As a

Two conﬁrmed cases suggest similar presentations to

result, the odds of infection in patients with cancer

nontransplant recipients and both patients demon-

were estimated to be 2.31 (95% CI: 1.89 to 3.02)

strated clinical improvement. A questionnaire of 87

greater. Patients with cancer who were infected had a

heart transplant recipients in China, of which

median age of 66 years and were more likely to have
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T A B L E 1 Select Treatment Trials Targeting RAS

Drug
Name

Mechanism
of Action

NCT Number

Title

Study Population

Losartan

Anti-RAS

NCT04312009

Losartan for Patients
With COVID-19
Requiring
Hospitalization

Age $18 yrs with presumptive positive
laboratory test for SARS-CoV-2;
admission to the hospital with a
sequential organ failure
assessment score $1 and increased
oxygen requirement;
randomization within 24 h of
presentation

Losartan

Anti-RAS

NCT04311177

Losartan for Patients
With COVID-19
Not Requiring
Hospitalization

Age $18 yrs with presumptive positive
laboratory test for SARS-CoV-2 or
URI or fever

Targeted
Enrollment

Study Design

Primary Outcome
Measure

200

Randomized, doubleblind, placebo
controlled

Difference in
oxygenation
status at 7 days

516

Randomized, doubleblind, placebo
controlled

Hospital admission
up to 15 days

For an up-to-date listing of trials, search for “COVID-19” at the ClinicalTrials.gov website.
COVID-19 ¼ coronavirus disease-2019; NCT ¼ national clinical trial; OFA ¼ organ failure assessment; RAS ¼ renin-angiotensin system; SARS-CoV-2 ¼ severe acute respiratory syndrome coronavirus-2;
URI ¼ upper respiratory infection.

non–small cell lung cancer (58.3%). Five of these pa-

MERS-CoV was established as the cause of MERS.

tients

chemotherapy,

Identiﬁcation and sequencing of the virus responsible

immunotherapy, or radiation therapy. Three deaths

for COVID-19 established that it was a novel CoV that

were

being

treated

with

were recorded.

shared 88% sequence identity with 2 bat-derived

In a multicenter, prospective cohort study of 2,007

SARS-like CoVs (16). Subsequently, the 2019 novel

cases from 575 hospitals, 1% of the 1,590 COVID-19

CoV was shown to share a 79.5% sequence homology

cases had a history of cancer (15). This in contrast to

with SARS-CoV and was subsequently renamed SARS-

an incidence of cancer in the Chinese population of

CoV-2 (16). The genome of the CoVs encodes 4 major

0.29% per 100,000 people. Again, among those

structural proteins: the spike (S) protein, nucleo-

infected, lung cancer was most common, and patients

capsid protein, membrane protein, and the envelope

tended to be older. Patients with cancer also suffered

protein (Central Illustration). The S protein is respon-

from an increased risk of adverse events that tended

sible for facilitating entry of the CoV into the target

to occur earlier, including admission to the intensive

cell (16,17) and is composed of a short intracellular

care unit, need for invasive ventilation, or death,

tail, a transmembrane anchor, and a large ectodomain

which occurred in 7 of 18 patients (39%), compared

that consists of a receptor binding S1 subunit and a

with 124 of 1,572 patients without cancer (8%). Pa-

membrane-fusing S2 subunit (16).

tients with cancer who were recently treated with
chemotherapy or surgery were also more likely to
suffer from clinically severe adverse events. However, there is a critical need for additional studies to
validate these early observations.

CoV VIROLOGY
Given that far more is known with respect to the
virology of SARS-CoV than of SARS-CoV-2, and given
that these 2 CoVs appear to have some overlapping

THE CoV FAMILY

biology and clinical presentations, we will discuss
these 2 viruses together, with an emphasis on the

CoVs represent a large family of hundreds of envel-

most recent studies that have revealed unique bio-

oped,

ribonucleic

logical aspects of SARS-CoV-2. We will review viral

acid (RNA) viruses that establish an infection pri-

attachment, entry, and replication of SARS-CoV and

marily by targeting the mucosal surfaces of respira-

SARS-CoV-2 in host cells. This discussion will be in-

tory and intestinal tracts of a wide range of mammals

tegrated with a review of the ongoing clinical trials

and birds. There are 4 main subgroupings of CoVs:

that target these different aspects of the biology of

alpha, beta, gamma, and delta (16). The 7 CoVs that

SARS-CoV-2 (Tables 1 to 5).

single-stranded,

positive-sense

are capable of infecting humans include 229E (alpha

Angiotensin-converting enzyme 2 (ACE2) is the

CoV), NL63 (alpha CoV), OC43 (beta CoV), HKU1 (beta

entry receptor for SARS-CoV and SARS-CoV-2. Viruses

CoV), Middle East respiratory syndrome (MERS)-CoV

enter cells by binding to host cell-encoded proteins

(beta CoV), SARS-CoV (beta CoV), and SARS-CoV-2

that facilitate the entry of the virus into the cell, as

(beta CoV). The prototype human CoV isolates 229E

well as allow the virus to survive and replicate within

and OC43 have been causally linked to the common

the cell. Some viruses, including certain strains of

cold. SARS-CoV is the cause of the SARS, whereas

CoVs are capable of down-modulating the entry

Ky and Mann
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T A B L E 2 Select Treatment and Prophylaxis Trials Targeting Viral Cell Entry

Drug Name

Mechanism of
Action

NCT Number

Title

Study Population

Targeted
Enrollment

Study Design

Primary Outcome
Measure

Treatment Trials
Camostat

Viral entry

NCT04321096

The Impact of Camostat
Mesylate on COVID-19
Infection (CamoCo-19)

Age 18–110 yrs, COVID-19–
conﬁrmed hospitalized
patients (<48 h) or if
hospital-acquired COVID19 is suspected, <48 h
since onset of symptoms

180

Randomized,
double-blind
placebo controlled,
phase IIa trial

Time to clinical
improvement at
30 days

Hydroxychloroquine

Viral entry

NCT04315896

Hydroxychloroquine
Treatment for Severe
COVID-19 Pulmonary
Infection (HYDRA Trial)

Age 18–80 yrs, COVID-19
conﬁrmed by RT-PCR in
any respiratory sample;
severe disease deﬁned by
pulse O2< 91%, 3%
decline from baseline
pulse O2, or need for
increased supplemental
O2, mechanical ventilation,
or sepsis

500

Randomized,
double-blind,
placebo controlled

All-cause hospital
mortality at
120 days

Viral entry

NCT04316377

Norwegian Coronavirus
Disease 2019 Study (NO
COVID-19)

Age >18 yrs, hospitalized,
moderately severe disease
(NEWS score #6);
SARS-CoV-2–positive test

202

Randomized, open, Rate of decline in
single arm
SARS-CoV viral load at
96 h

Chloroquine
phosphate

Viral entry

NCT04303507

Chloroquine/
Hydroxychloroquine
Prevention of Coronavirus
Disease (COVID-19) in the
Healthcare Setting
(COPCOV)

Age $16 yrs; health care
worker or front-line
participant with patient
contact working in a
health care facility;
inpatient or relative of a
patient and likely exposed
to COVID-19; agree to not
self-medicate with
potential antivirals

40,000

Randomized,
double-blind,
placebo controlled

Number of
symptomatic
COVID-19
infections
Severity of
symptoms

Hydroxychloroquine

Viral entry

NCT04308668

Post-exposure
Prophylaxis/Pre-emptive
Therapy for SARSCoronavirus-2 (COVID-19
PEP)

Age >18 yrs; exposure to a
COVID-19 case within
4 days as either a health
care worker or household
contact; symptomatic
COVID-19 case with
conﬁrmed diagnosis within
4 days of symptom onset;
or symptomatic health
care worker with known
COVID-19 contact and
within 4 days of symptom
onset

3,000

Randomized,
double-blind,
placebo controlled

Incidence of
COVID-19 disease
at 14 days
Ordinal Scale of
COVID-19 disease
severity at 14 days

Hydroxychloroquine

Viral entry

NCT04318444

Hydroxychloroquine Post
Exposure Prophylaxis for
Coronavirus Disease
(COVID-19)

Age >18 yrs; household
contact of index case:
currently residing in the
same household as an
individual evaluated at
NYP via outpatient, ED, or
inpatient services who: 1)
tests positive for COVID-19;
or 2) is deﬁned as
suspected case, or PUI, by
the treating physician

1,600

Randomized,
double-blind,
placebo controlled

Symptomatic, labconﬁrmed COVID19

Hydroxychloroquine

Viral entry

NCT04318015

Hydroxychloroquine
Chemoprophylaxis in
Healthcare Personnel in
Contact With COVID-19
Patients (PHYDRA Trial)

Age >18 yrs; health care
personnel exposed to
patients with COVID-19
respiratory disease
(physicians, nurses,
chemists, pharmacists,
janitors, stretcher-bearer,
administrative, and
respiratory therapists)

400

Randomized,
double-blind,
placebo controlled

Symptomatic
COVID-19 infection
rate at 60 days

Hydroxychloroquine

Prophylaxis Trials

For an up-to-date listing of trials, search for “COVID-19” at the ClinicalTrials.gov website.
ED ¼ emergency department; NEWS ¼ National Early Warning Score; NYP ¼ New York Presbyterian; PUI ¼ person under investigation; RT-PCR ¼ reverse transcriptase-polymerase chain reaction; other
abbreviations as in Table 1.
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T A B L E 3 Select Treatment Trials Targeting Viral Replication

Drug Name

Mechanism
of Action

NCT Number

Title

Study Population

Targeted
Enrollment

Study Design

Primary Outcome
Measure

Antiretroviral

NCT04260594

Clinical Study of Arbidol Age $18 yrs; subjects with
Hydrochloride Tablets
pneumonia diagnosed as
in the Treatment of
2019-nCoV infection;
Pneumonia Caused by
detection of 2019-nCoV
Novel Coronavirus
nucleic acid–positive by
RT-PCR in respiratory tract
or blood samples; virus
gene sequence of
respiratory tract or blood
samples is highly
homologous to the known
2019-nCoV

380

Randomized, singlearm, open-label
umifenovir

Negative viral
conversion rate at
7 days

ASC09 þ
Antiretroviral
ritonavir;
lopinavir þ
ritonavir

NCT04261907

Evaluating and
Age between 18 to 75 yrs; lab
Comparing the Safety
(RT-PCR) and clinically
and Efﬁciency of
conﬁrmed case of 2019nCoV pneumonia;
ASC09/Ritonavir and
Lopinavir/Ritonavir
hospitalized with a new
for Novel Coronavirus
onset respiratory illness
(#7 days since illness
Infection
onset)

160

Randomized, openlabel ASC09/
ritonavir or
lopinavir/ritonavir

The incidence of
adverse outcomes,
deﬁned by at least 1
of the following:
pulse O2 #93%
without O2
supplementation,
PaO2-to-FiO2
ratio #300 or
RR $30 breaths/
min assessed at
14 days

Darunavir þ
cobicistat

Antiretroviral

NCT04252274

Efﬁcacy and Safety of
Darunavir and
Cobicistat for
Treatment of COVID19 (DC-COVID-19)

Pneumonia caused by 2019nCoV

30

Randomized, openlabel, single-arm

The viral clearance rate
of throat swabs,
sputum, or lower
respiratory tract
secretions at day 7

Lopinavir þ
ritonavir;
umifenovir

Antiretroviral

NCT04252885

The Efﬁcacy of Lopinavir Age 18–80 yrs; conﬁrmation
Plus Ritonavir and
of SARS-CoV-2 infection
Arbidol Against Novel
by RT-PCR with normal
Coronavirus Infection
kidney and liver function
(ELACOI)

125

Randomized, openlabel (1:1:1) to
lopinavir þ
ritonavir; or
umifenovir; or
standard care

The rate of viral
inhibition, as
determined by RTPCR at days 2, 4, 7,
10, 14, and 21

Lopinavir þ
ritonavir

Antiretroviral

NCT04330690

Treatments for COVID-19: Age >6 months with
Canadian Arm of the
conﬁrmed SARS-CoV-2 by
RT-PCR, admitted to
SOLIDARITY Trial
(CATCO)
hospital

440

Randomized, openEfﬁcacy of intervention
label (1:1) of
at 29 days as
lopinavir þ ritonavir
determined by 10or standard care
point ordinal scale
of clinical status

Remdesivir

Antiretroviral

NCT04280705

Adaptive COVID-19
Treatment Trial
(ACTT)

572

Adaptive, randomized,
double-blind
placebo controlled

Time to recovery at
day 29

Remdesivir

Antiretroviral

NCT04292899

Study to Evaluate the
Age $18 yrs; conﬁrmation of
Safety and Antiviral
SARS-CoV-2 infection by
Activity of Remdesivir
RT-PCR #4 days before
(GS-5734) in
randomization; current
Participants With
hospitalization with pulse
Severe Coronavirus
O2# 94%
Disease (COVID-19)

6,000

Randomized, openlabel study of
remdesivir 5 days;
or remdesivir
10 days

Odds of clinical
improvement on a
7-point ordinal
scale by day 11

Remdesivir

Antiretroviral

NCT04292730

Study to Evaluate the
Age $18 yrs; conﬁrmation of
Safety and Antiviral
SARS-CoV-2 infection by
Activity of Remdesivir
RT-PCR #4 days before
(GS-5734) in
randomization; current
Participants With
hospitalization with fever,
Moderate Coronavirus
pulse O2 >94%,
radiographic evidence of
Disease (COVID-19)
pulmonary inﬁltrates
Compared to Standard
of Care Treatment

1,600

Randomized, openOdds of clinical
label study of
improvement on a
remdesivir 5 days;
7-point ordinal
or remdesivir
scale by day 11
10 days; or standard
of care

Umifenovir

Age 18–99 yrs, PCR-conﬁrmed
novel coronavirus
infection by lab assay;
illness as deﬁned by
abnormal radiographic
imaging, clinical
assessment, and pulse
O2 #94%, requiring O2, or
requiring mechanical
ventilation

For an up-to-date listing of trials, search for “COVID-19” at the ClinicalTrials.gov website.
ECMO ¼ extracorporeal membrane oxygenation; FiO2 ¼ fraction of inspired O2; nCoV ¼ novel coronavirus; PaO2 ¼ partial arterial O2 pressure; PCR ¼ polymerase chain reaction; RR ¼ respiratory rate; other
abbreviations as in Tables 1 and 2.
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T A B L E 4 Select Treatment and Prophylaxis Trials Targeting the Immune System

Drug Name

Mechanism
of Action

NCT Number

Title

Study Population

Targeted
Enrollment

Study Design

Primary Outcome
Measure

Treatment Trials
IFN-a1b

Immunomodulatory NCT04293887 Efﬁcacy and Safety of
IFN-a1b in the
Treatment of
Novel
Coronavirus
Patients

Age $18 yrs with clinically
diagnosed coronavirus
pneumonia within
7 days, including RTPCR evidence of
coronavirus and
symptoms

328

Randomized, openlabel, single-arm

Incidence of side
effects within
14 days including
dyspnea, pulse
O2 #94%, and
RR $24 breaths/
min

Methylprednisolone

Immunomodulatory

NCT04273321 Efﬁcacy and Safety of
Corticosteroids
in COVID-19

Age >18 yrs, diagnosis of
novel coronavirus
pneumonia (COVID-19)

400

Randomized, openlabel, single-arm

Incidence of
treatment failure
in 14 days

Methylprednisolone

Immunomodulatory

NCT04244591 Glucocorticoid
Therapy for
COVID-19
Critically Ill
Patients With
Severe Acute
Respiratory
Failure

Age >18 yrs, RT-PCR–
conﬁrmed infection,
symptoms for >7 days,
PaO2/FiO2 <200,
positive pressure
ventilation or HFNC
higher than 45 l/min
for <48 h, requiring ICU
admission

80

Randomized, openlabel of
glucocorticoid
therapy or standard
of care

Murray lung injury
score at 7 days

Sarilumab

Immunomodulatory

NCT04315298 Evaluation of the
Efﬁcacy and
Safety of
Sarilumab in
Hospitalized
Patients With
COVID-19

Age $18 yrs; conﬁrmation
of SARS-CoV-2 infection
by RT-PCR; current
hospitalization with
evidence of pneumonia
and severe disease,
critical disease, or
multiorgan system
dysfunction

400

Adaptive, randomized,
double-blind,
placebo-controlled
with high and low
doses

Percent change in Creactive protein
levels at 4 days
Percentage of
patients
reporting clinical
severity rated on
a 7-point ordinal
scale

Siltuximab

Immunomodulatory NCT04329650 Efﬁcacy and Safety of
Siltuximab vs.
Corticosteroids in
Hospitalized
Patients With
COVID-19
Pneumonia

Age $18 yrs; conﬁrmation
of SARS-CoV-2 infection
by RT-PCR; current
hospitalization with
evidence of pneumonia;
maximum O2 support of
35%

100

Randomized, openlabel of siltuximab
or
methylprednisolone

Proportion of
patients
requiring ICU
admission at
29 days

Tocilizumab

Immunomodulatory

NCT04317092 Tocilizumab in
COVID-19
Pneumonia
(TOCIVID-19)

No age or sex limit; SARSCoV-2 infection by RTPCR, current
hospitalization
secondary to
pneumonia; pulse
O2 #93%, requiring O2,
or requiring mechanical
ventilation (invasive or
noninvasive)

400

Open-label, single-arm

Mortality at 1 month

Tocilizumab

Immunomodulatory

NCT04320615 A Study to Evaluate
the Safety and
Efﬁcacy of
Tocilizumab in
Patients With
Severe COVID-19
Pneumonia
(COVACTA)

Age $18 yrs; hospitalized
with COVID-19
pneumonia per WHO
criteria; pulse O2 #93%
or PaO2/FiO2 <300

330

Randomized, doubleblind placebo
controlled

Clinical status using
a 7-category
ordinal scale at
28 days

Age $18 yrs; hospitalized with
conﬁrmed COVID-19
diagnosis by RT-PCR or
other laboratory test;
hypoxia deﬁned by PaO2/
FiO2; CXR or CT scan with
bilateral inﬁltrates

342

Randomized,
Time to clinical
open-label (1:1:1:1)
improvement at
to anakinra, or
15 days
siltuximab, or
anakinra þ siltuximab,
or tocilizumab, or
anakinra þ tocilizumab

Anakinra, siltuximab,
or tocilizumab

Immunomodulatory NCT04330638 Treatment of
COVID-19 Patients
With Antiinterleukin Drugs
(COV-AID)

Recombinant human
IFN-a1b and
thymosin a1

Immunomodulatory NCT04320238 Experimental Trial of
rhIFNa Nasal
Drops to Prevent
2019-nCOV in
Medical Staff

Prophylaxis Trial
Age 18 to 65 yrs, formally
serving as medical staff
in Taihe Hospital

2,944

2-arm, open-label to
IFN-a1b in a lowrisk group and IFNa1b and thymosin a1
in a high-risk group

New COVID-19
diagnosis at
28 days

For an up-to-date listing of trials, search for “COVID-19” at the ClinicalTrials.gov website.
CT ¼ computed tomography; CXR ¼ chest x-ray; HFNC ¼ high ﬂow nasal cannula; ICU ¼ intensive care unit; IFN ¼ interferon; rhIFN ¼ recombinant human interferon; WHO ¼ World Health Organization;
other abbreviations as in Tables 1 to 3.
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receptor once they gain access to the cell. Receptor

ACE2 is 10- to 20-fold higher than the binding of the

down-modulation is a strategy broadly used by many

SARS-CoV ectodomain to ACE2 (17). The increase in

viruses to escape the immune system, as well as

stickiness of the SARS-CoV-2 capsid S protein makes

establish the best environment for viral replication

disease transmission more likely and might explain

and spread (18). Receptor down-modulation may also

the increased person-to-person transmission with

disrupt many of the natural physiologic functions of

SARS-CoV-2 compared with that of SARS-CoV. Insofar

the host cell, resulting in cell death leading to organ

as the viral S proteins are the part of the virus that

level dysfunction.

interacts with the immune system, they may serve as

The entry receptor utilized by both SARS-CoV and

a promising target for vaccines. Relevant to this dis-

SARS-CoV-2 is ACE2 (Central Illustration), which is a

cussion, convalescent sera from patients with SARS

type I transmembrane carboxypeptidase with 40%

have been shown to block the entry of SARS-CoV-2

homology to ACE. ACE plays a critical role in activa-

entry into cultured cells, albeit with less efﬁciency

tion of the RAS, by processing angiotensin I (angio-

that SARS-CoV (23). However, monoclonal antibodies

tensin 1-10) to angiotensin II (angiotensin 1-8), the

raised against the receptor binding domain of the S1

major effector peptide of RAS, which mediates its

protein of SARS-CoV do not bind to the receptor

effects through selective interactions with G-protein–

binding domain of the S1 protein of SARS-CoV-2,

coupled angiotensin II type 1 (AT1) and type 2 (AT2)

suggesting that SARS-directed antibodies are not

receptors (19). ACE, however, has not been implicated

cross reactive and that SARS-CoV-2 proteins are

in the entry of human CoVs into cells.

necessary to develop effective antibodies. Although

ACE2 is highly expressed in the mouth, tongue,

ACE inhibitors do not inhibit ACE2, Hoffman et al. (23)

and types I and II alveolar epithelial cells in the lungs.

demonstrated that anti-ACE2 antibody prevented

ACE2 is also abundantly expressed by cardiovascular

entry of viral vectors into cell lines expressing the

endothelium, cardiac myocytes, cardiac ﬁbroblasts,

SARS-CoV-2 S protein.

as well as epithelial cells of the kidney and testis. The

INTERACTION OF CoV WITH THE RAS. An additional

major substrate of ACE2 is angiotensin II, which is

layer of complexity to understanding the patho-

cleaved to angiotensin 1-7 (Figure 1) and functions

physiology of the SARS-CoV-2 in humans stems from

through association with the G-protein–coupled re-

the complexity of the interactions of CoVs with the

ceptor Mas receptor. The ACE2–angiotensin (1–7)–Mas

RAS (Figure 1), as well as the widespread use of drugs

receptor axis is regarded as the counter-regulatory

that

arm of the RAS by opposing the effects of the ACE–

inhibitors,

angiotensin II axis–AT1. Although the precise role of

angiotensin receptor-neprilysin inhibitors. Each of

ACE2 is still being evaluated, studies been shown that

these drugs has different effects on the expression of

ACE2 exerts protective effects in the pulmonary and

the various components of the RAS in different tissue

the cardiovascular systems, where it serves to

beds. Here we will brieﬂy discuss these important

oppose the deleterious effects of RAS activation

interactions, as well as their implications for the

(20–22).

treatment of patients with COVID-19.

interfere

with

the

RAS,

angiotensin-receptor

including
antagonists,

ACE
or

Infection with SARS-CoV and SARS-CoV-2 is trig-

Previous studies have shown that SARS-CoV S

gered by binding of the S protein on the surface of the

proteins induce the expression of a cell surface

CoV to ACE2 that is expressed on the cell surface. The

metalloenzyme

receptor binding domain of the S protein of SARS-

metalloproteinase-17, which was originally described

CoV-2 is located on the S1 subunit, which undergoes

as the enzyme that cleaves membrane-bound tumor

a conformational change when it binds to ACE2,

necrosis factor-a from the cell surface and allows it

termed

a

disintegrin

and

which facilitates viral attachment to the surface of

circulate in the soluble form of tumor necrosis factor-a

target cells (17). Binding of SARS-CoV-2 to ACE2 can

(24). As shown in Figure 1, activation of a disintegrin

result in uptake of virions into endosomes (Central

and metalloproteinase-17 results in the proteolytic

Illustration). Viral entry into the cell requires prim-

cleavage of ACE2 (referred to as shedding) from the

ing of the S protein by the serine protease trans-

cell surface, with the release of the catalytically active

membrane protease serine 2 (TMPRSS2), which

soluble angiotensin-converting enzyme 2 (sACE2)

cleaves the viral S protein at the S1/S2 and the S2 0 site

ectodomains into the circulation (22,25). A decrease in

and allows fusion of viral and cellular membranes

ACE2 levels on the cell surface would be expected to

(23). The S proteins of SARS-CoV-2 can also use pH-

result in a decrease in the levels of angiotensin 1-7

sensitive endosomal proteases (cathepsin B and L)

(cytoprotective) and a corresponding increase in tis-

for priming and entry into cells. Interestingly, the

sue levels of angiotensin II (proinﬂammatory and

binding afﬁnity of the SARS-CoV-2 S ectodomain to

proﬁbrotic). The importance of SARS-CoV2–induced
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T A B L E 5 Select Treatment Trials With Multiple Targets

Drug Name

Mechanism of Action

NCT Number

Title

Lopinavir þ ritonavir; ribavirin; IFN-b1b

Antiretroviral and immunomodulatory NCT04276688

Lopinavir/Ritonavir, Ribavirin and IFN-beta Combination for
nCoV Treatment

Lopinavir þ ritonavir; hydroxychloroquine

Antiretroviral and viral entry

NCT04307693

Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in
Patients With Mild Coronavirus Disease (COVID-19)

Remdesivir þ hydroxychloroquine;
remdesivir; hydroxychloroquine

Antiretroviral and viral entry

NCT04321616

Efﬁcacy of Different Anti-viral Drugs in COVID-19 Infected
Patients

Combinations of oseltamivir, chloroquine,
Antiretroviral and viral entry
darunavir, ritonavir, lopinavir, oseltamivir,
favipiravir

NCT04303299

Various Combination of Protease Inhibitors, Oseltamivir,
Favipiravir, and Hydroxychloroquine for Treatment of
COVID19: A Randomized Control Trial (THDMS-COVID-19)

Favipiravir; chloroquine phosphate

Antiretroviral and viral entry

NCT04319900

Clinical Trial of Favipiravir Tablets Combined With
Chloroquine Phosphate in the Treatment of Novel
Coronavirus Pneumonia

Remdesivir; lopinavir þ ritonavir; IFN-b1a;
hydroxychloroquine

Antiretroviral, viral entry, and
immunomodulatory

NCT04315948

Trial of Treatments for COVID-19 in Hospitalized Adults
(DisCoVeRy)

Favipiravir þ tocilizumab

Antiretroviral and immunomodulatory NCT04310228

Favipiravir Combined With Tocilizumab in the Treatment of
Corona Virus Disease 2019

For an up-to-date listing of trials, search for “COVID-19” at the ClinicalTrials.gov website.
IL ¼ interleukin; other abbreviations as in Tables 1 to 4.

Continued on the next page

down-regulation of cell surface ACE2 was demon-

early stages of SARS-CoV-2 infections in cell culture

strated in experimental studies, wherein administra-

and human tissue organoid cultures (29). APN01 has

tion of recombinant human ACE2 protein, genetic

already undergone safety and tolerability testing in a

deletion of the AT1 receptor, or administration of an

phase II trial of healthy volunteers (NCT00886353),

AT1 receptor antagonist were shown to be protective

but at the time of this writing is not being tested

in acute lung injury models (21,22). These and other

clinically in patients with COVID-19.

observations have suggested that the use of AT1 re-

The recognition that many patients with COVID-19

ceptor antagonists may be beneﬁcial in patients with

have underlying medical conditions that are treated

COVID-19 (26), and consistent with this, losartan is

with ACE inhibitors and AT1 receptor antagonists

currently being tested in randomized, double-blind

(30), coupled with the knowledge that higher urinary

placebo controlled studies as a potential therapy in

ACE2 levels have been observed in patients treated

hospitalized infected patients (Table 1). Relevant to

with AT1 receptor antagonists (26), has given rise to

this discussion, the ACE inhibitors in clinical use do

the concern that pharmacologic up-regulation of

not directly affect ACE2 activity (27). The biological

ACE2 by RAS inhibitors may inﬂuence the infectivity

signiﬁcance of circulating sACE2 is not known. Of

of SARS-CoV-2 in a patient population that is already

note, sACE2 retains its ability to bind the S protein of

at high risk for severe COVID-19 infection (31). How-

SARS-CoV and was shown to prevent entry of SARS-

ever, as noted in a recent review (32) on this topic, the

CoV into cells in vitro (28). Thus, sACE2 may act as a

experimental and clinical data often yield conﬂicting

decoy receptor that prevents SARS-CoV-2 from bind-

results with respect to the role of ACE inhibitors and

ing to ACE2 on the cell surface. APN01 is a human

AT1 receptor antagonists on ACE2 levels in different

recombinant sACE2 that has been shown to block the

pathophysiological contexts. These conﬂicting results
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T A B L E 5 Continued

Targeted
Enrollment

Study Population

Study Design

Primary Outcome Measure

Age $18 yrs hospitalized for virologically
conﬁrmed 2019-nCoV infection with NEWS $1
on recruitment; febrile with symptoms and
duration of symptoms #10 days

127

Randomized, open-label (1:1:1) to lopinavir þ
ritonavir; or ribavirin; or IFN-b1b

Time to negative nasopharyngeal viral RT-PCR
assessed up to 1 month

Age 16–99 yrs with conﬁrmed mild COVID-19
(NEWS 0–4)

150

Randomized, open-label (1:1:1) lopinavir þ ritonavir;
or hydroxychloroquine; or standard care

Viral load at hospital days 3, 5, 7, 10, 14, 18

Age $18 yrs with conﬁrmed SARS-CoV-2 by RTPCR, admitted to hospital or ICU

700

Randomized, Open-Label (1:1:1) remdesivir; or
hydroxychloroquine; or remdesivir þ
hydroxychloroquine adaptive controlled design;
comparison with standard of care

In-hospital mortality at 3 weeks

Age 16–100 yrs with COVID-19 diagnosis

320

Randomized, open-label, oseltamivir þ chloroquine;
or darunavir þ ritonavir þ oseltamivir; or
lopinavir þ ritonavir þ oseltamivir; or
favipiravir þ lopinavir þ ritonavir; or darunavir þ
ritonavir þ oseltamivir þ chloroquine; or
darunavir þ ritonavir þ favipiravir þ chloroquine

Time to negative detection of SARS-CoV-2 in
nasopharyngeal swab at 24 weeks

Age 18–75 yrs; diagnosed with nCoV pneumonia
with a course of illness no more than 14 days;
if the course is >14 days, no progression by
chest radiograph within 7 days; respiratory
symptoms; positive COVID-19 RT-PCR within
3 days

150

Randomized, double-blind 3-arm study of
favipiravir þ chloroquine; or favipiravir; or
placebo

Time to improvement of respiratory symptoms
Number of days of viral shedding
Frequency of improvement of respiratory
symptoms

Age $18 yrs, laboratory-conﬁrmed SARS-CoV-2
infection as determined by RT-PCR or other
assay <72 h prior to randomization,
hospitalized patients with illness of any
duration, and pulmonary exam abnormalities
and pulse O2 # 94%, requiring O2, or
requiring mechanical ventilation, or acute
respiratory failure requiring mechanical
ventilation and/or supplemental O2

3,100

Adaptive, randomized, open-label 1:1:1:1:1 to
remdesivir; or lopinavir/ritonavir; or lopinavir/
ritonavir þ INF-b1a; or hydroxychloroquine; or
standard of care

Percentage of subjects reporting disease severity
on a 7-point ordinal clinical scale reﬂective of
hospitalization and oxygenation status; or
death at 15 days

Age 18–65 yrs, COVID-19 diagnosis,
increased IL-6

150

Randomized, open-label (1:1:1) of favipiravir þ
tocilizumab; or favipiravir; or tocilizumab

Clinical cure rate at 3 months

suggest that the effects on RAS inhibitors on ACE2 are

endocytic machinery, by binding to a cell surface

complex and nuanced and should not be assumed to

receptor, which then triggers endocytosis of the

be the same for all RAS inhibitors, nor should it be

virus-receptor complex (Central Illustration). In the

assumed that changes in ACE2 levels in the heart or

endocytic pathway, the endocytosed virions are

other tissues necessarily reﬂect changes in ACE2

subjected to an activation step within the endosome,

levels in the lung, which is the portal of entry for

which is typically mediated by the acidic environ-

SARS-CoV-2. Given that we have limited under-

ment of the endosome, resulting in fusion of the viral

standing with respect to the interaction of RAS in-

and endosomal membranes, which allows for the

hibitors, ACE2 levels, and SARS-CoV-2 infectivity in

release of the viral genome into the cytosol. Several

humans, we do not believe that it is possible to make

viruses, including human immunodeﬁciency virus

deﬁnitive statements that go beyond the joint state-

and SARS-CoV use direct membrane fusions at the

ment issued on March 17, 2020, by the Heart Failure

cell surface or endocytosis to enter cells. As noted,

Society of America, American College of Cardiology,

recent studies suggest that SARS-CoV-2 binds to

and American Heart Association, that recommended

ACE2, which leads to endocytosis of the receptor-

“continuing

system

virus complex (23). What is not known at this time

antagonists for those patients who are currently pre-

is whether SARS-CoV-2 is also capable of directly

scribed such agents for indications for which these

fusing with the lipid membrane of cells. However,

agents are known to be beneﬁcial” (33).

based on the similarities of how SARS-CoV and SARS-

ENTRY

OF

renin-angiotensin-aldosterone

SARS-CoV

AND

SARS-CoV-2

INTO

CoV-2 behave, it is likely that their modes of entry

CELLS. The entry of enveloped viruses into host cells

into cells will be similar. Understanding these dif-

occurs through 2 primary mechanisms: the ﬁrst is

ferences in cell entry has implications for developing

direct fusion of the viral membrane with the plasma

novel therapeutics.

membrane of the host cells, which allows the virus to
directly deliver its genomic material into the cytosol;

THERAPEUTICS

and the second is that the virus hijacks the cell’s

entry of SARS-CoV into cells was shown to occur by

TARGETING

ENDOCYTOSIS. The
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F I G U R E 1 Interaction of CoVs With the RAS

Angiotensin-converting enzyme (ACE) converts angiotensin I (ANG1) (angiotensin 1-10) to angiotensin II (ANG2) (angiotensin 1-8), which is
the major effector peptide of the renin-angiotensin system (RAS). ANG2 mediates its effects through selective interactions with G-protein–
coupled angiotensin II type 1 receptor (AT1R) and G-protein–coupled angiotensin II type 1 type 2 receptor (AT2R). ANG2 is degraded to ANG-(17) by angiotensin-converting enzyme 2 (ACE2), ANG-(1-7) binds to the Mas receptor (not shown). The ACE2–ANG-(1-7)–Mas receptor axis
opposes the effects of ACE–ANG2–AT1 axis. The binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein
to ACE2 induces ACE2 shedding by activating a disintegrin and metalloproteinase-17 (ADAM-17). A decrease in ACE2 levels would be expected to result in a decrease in the levels ANG-(1-7) levels (cytoprotective) and a corresponding increase in tissue levels of ANG2 (proinﬂammatory and proﬁbrotic). Transmembrane serine protease 2 (TMPRSS2), a type II cell membrane serine protease that activates the spike
protein of SARS-CoV-2 and allows it to bind to ACE2. Modiﬁed from Simmons et al. (25). CoVs ¼ coronaviruses; P ¼ phosphorylation.

direct fusion of the viral membranes with the plasma

clinical trials with SARS-CoV-2 (Table 2). Camostat

membrane of the host cell (Central Illustration),

mesylate has already been shown to inhibit replica-

through a process that requires processing of the viral

tion of inﬂuenza and parainﬂuenza viruses and to

S protein by TMPRSS2 at or near the cell surface.

prevent the development of pneumonia and viral

Processing of the S protein exposes the fusion peptide

myocarditis in infected mice (36). Given that the

of the S protein that inserts into the cell membrane,

SARS-CoV-2 S protein is activated by the pH-

which brings the envelope of the viral membrane into

dependent cysteine protease cathepsin L, this pro-

closer approximation with the membrane of the host

cessing step may be sensitive to inhibition with drugs

cell, thereby facilitating fusion (34). At the time of

that indirectly inhibit cathepsin L activity by inter-

this writing, the uptake of SARS-CoV-2 into cells has

fering with endosomal acidiﬁcation (e.g., baﬁlomycin

been shown to occur through endocytosis of the

A1) or by compounds that directly block the proteo-

SARS-CoV-2–ACE2 complex, which also requires

lytic activity of cathepsin L.

priming of the S protein by TMPRSS2. It is not known

At the time of this writing, it has also been sug-

whether SARS-CoV-2 also enters though direct fusion.

gested that the antimalarial drugs chloroquine and

Based on the evidence linking TMPRSS2-mediated

hydroxychloroquine might exert a potent antiviral

SARS-CoV-2 activation to SARS-CoV-2 infectivity

effect by virtue of their ability to increase endosomal

(23,35), the small molecule serine protease inhibitor

pH. Inside cells, chloroquine and hydroxychloroquine

camostat mesylate may also be an attractive target for

are

rapidly

protonated

and

concentrated

in
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endosomes. The positive charge of the chloroquine

Once the genomic RNA of SARS-CoV is released into

increases the pH of the endosome, which prevents

the cytoplasm of the host cell, the positive-strand viral

cathepsin-induced priming of the viral S protein. Both

RNA is translated on host ribosomes into a large poly-

chloroquine and hydroxychloroquine decrease SARS-

peptide termed the replicase, which undergoes pro-

CoV-2

however,

teolytic cleavage to yield proteins that are required

hydroxychloroquine is more potent than chloroquine

from genome replication, including a viral RNA-

(37). In a small single-arm study of patients with

dependent

conﬁrmed

hydroxy-

dependent RNA polymerase generates a full-length,

replication

in

COVID-19,

cultured

treatment

cells;

with

RNA

polymerase.

The

viral

RNA-

chloroquine was associated with a signiﬁcant differ-

antisense negative-strand viral RNA template, which

ence in clearing of viral nasopharyngeal carriage of

is used for replicating positive strand viral genomic

SARS-CoV-2 within 3 to 6 days when compared with

RNA, as well as shorter subgenomic negative strand

that of untreated control subjects that were studied at

RNAs that serve as templates for synthesizing

3 to 6 days. Azithromycin when added to hydroxy-

messenger RNAs that code for structural proteins of

chloroquine was signiﬁcantly more efﬁcient for virus

the virus, including the S, membrane, envelope, and

elimination (38). However, both therapies can result

nucleocapsid proteins. Translation of viral messenger

in QT prolongation, and as such, caution needs to be

RNAs occurs using the host endoplasmic reticulum.

exercised when using these therapies together.

Once the viral structural proteins, S, envelope, and

Chloroquine and hydroxychloroquine can also mani-

membrane, are translated in the endoplasmic reticu-

fest in cardiotoxicity, including cardiomyopathy,

lum, they move along the secretory pathway to the

both systolic and diastolic, atrioventricular block, and

endoplasmic reticulum-Golgi intermediate compart-

bundle branch block (39). Hydroxychloroquine will be

ment. There, the viral proteins become encapsulated

used as one of the treatment arms in the World Health

and bud into membranes containing viral structural

Organization (WHO) multinational SOLIDARITY (Ef-

proteins. Following assembly and maturation, virions

ﬁcacy of Different Antiviral Drugs in SARS-CoV-2)

are transported to the cell surface in vesicles and

trial (40) and is also currently being investigated in

released by exocytosis (43,44).

a number of other studies (Tables 2 and 5). Interestingly, amiodarone, which is a cationic amphiphile,
was shown to inhibit Ebola virus infection in vitro in
target cells, using concentrations of amiodarone that
overlapped those detected in the sera of patients

THERAPEUTICS FOR VIRAL REPLICATION. There are

a number of antiviral drugs that are being repurposed
for the treatment of SARS-CoV-2. A partial list of these
antiviral drugs are discussed next.

treated for arrhythmias. Both amiodarone and its

N u c l e o s i d e a n a l o g s . Remdesivir (GS-5734, Gilead

main metabolite, monodesethyl amiodarone, were

Sciences, Inc., Foster City, California) is a nucleoside

shown to interfere with the fusion of the viral enve-

analog that exhibits broad antiviral activity. Remde-

lope with the endosomal membrane, thus blocking

sivir is a prodrug that is metabolized to its active form

viral replication (41). Amiodarone has also been

GS-441524, which interferes with the action of viral

shown to inhibit SARS-CoV infection and spreading

RNA-dependent RNA polymerase, resulting in a

in vitro by altering the late compartments of the

decrease in viral RNA production. It is not known,

endocytic pathway by acting after the transit of the

however, whether remdesivir terminates RNA chains

virus through endosomes (42).

or causes mutations in them. Remdesivir was effective against multiple types of CoVs in cell culture and

REPLICATION

OF

SARS-CoV

IN

HOST

CELLS.

a mouse model of SARS (45); however, it did not show

Because of the exceptionally large size of the CoV

an effect in patients with Ebola. Remdesivir is

RNA genome (w30 kb) and the complexity of CoV-

currently being tested in several clinical trials for

host cell interactions, coupled with the novelty of

hospitalized patients with COVID-19 and pneumonia

the

SARS-CoV-2

genome,

very

little

is

known

(Tables 3 and 5). Remdesivir is also 1 of the 4 treat-

regarding SARS-CoV-2 replication in cells, let alone

ment arms in the multinational SOLIDARITY trial,

how the virus interacts with the host. Given that

which is the World Health Organization’s sponsored

antiviral strategies are being considered for treatment

multinational randomized, open clinical trial to

of patients with COVID-19, here we will review what

evaluate the safety and comparative efﬁcacy of

is generally understood about SARS-CoV replication

hydroxychloroquine, remdesivir, the combination of

in mammalian cells, recognizing that this information

lopinavir and ritonavir, and the combination lopina-

may change as we learn more about SARS-CoV-2

vir and ritonavir plus interferon-beta (40). SOLI-

(see Figure 2).

DARITY will use an adaptive design, which will allow
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F I G U R E 2 The Replication Strategy of SARS-CoV

(a) The severe acute respiratory syndrome coronavirus (SARS-CoV) spike (S) glycoprotein attaches to the angiotensin-converting enzyme 2
(ACE2) receptor on the cell surface. On entering the cytoplasm, the viral core particle, which contains the positive (50 to 30 ) strand genomic
ribonucleic acid (RNA), is released into the cytoplasm of the cell (b). The positive-strand viral RNA is translated on host ribosomes to generate
a large polyprotein (c) that undergoes proteolytic processing to generate multiple viral proteins, including an RNA-dependent RNA polymerase (RdRp). The RNA-dependent RNA polymerase generates a full-length, antisense negative-strand (30 to 50 ) viral RNA strand (d) that
serves as template for replicating positive-strand viral genomic RNA, as well as shorter negative-strand RNAs (e) that serve as templates for
synthesizing messenger ribonucleic acids (mRNAs) that code for structural proteins of the virus (f), including the S, membrane (M), envelope
(E), and nucleocapsid (N) proteins. Translation of viral mRNAs occurs using the host endoplasmic reticulum (ER) (g). Once the viral structural
proteins, S, E, and M, are translated and inserted into the ER, they move along the secretory pathway to the endoplasmic reticulum-Golgi
intermediate compartment (ERGIC) (h). The viral proteins become encapsulated and bud into membranes containing viral structural proteins,
where mature virions are assembled. (i) Following assembly, virions are transported to the cell surface in vesicles and released by exocytosis.
Modiﬁed from Turner et al. (43). ORF ¼ open reading frame.

for discontinuation of drugs that lack effectiveness,

drug that inhibits viral RNA-dependent RNA poly-

as well as adding new drugs that appear promising.

merase. Like remdesivir, it is a prodrug that is

This type of trial design offers ﬂexibility and efﬁ-

metabolized to its active form, favipiravir-ribofur-

ciency, particularly in the identiﬁcation of early sig-

anosyl-5’-triphosphate. Although favipiravir has un-

nals related to either efﬁcacy or toxicity, while

dergone phase III clinical trials for the treatment of

maintaining study validity (46).

inﬂuenza, it is not yet approved by the U.S. Food

Favipiravir (Avigan, Fujiﬁlm Toyama Chemical,
Tokyo, Japan) is another nucleoside analog antiviral

and

Drug

Administration

(FDA).

Japan

has

granted approval for favipiravir for treating viral
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In

immune cells following antigen stimulation. Both

preliminary studies, favipiravir was shown to have

unresponsive

to

current

antivirals.

type I and type II IFNs provoke the synthesis of

more potent antiviral activity than lopinavir/ritona-

proteins that have antiviral and immunomodulatory
effects. Recombinant IFN-b has been shown to

vir (47).
Ribavirin (Copegus, Genentech Inc., San Francisco,

inhibit SARS-CoV replication in vitro more effec-

California) is a prodrug that acts as nucleoside in-

tively than either IFN-a or IFN-g (49,50). Interest-

hibitor. The metabolites of ribavirin resemble aden-

ingly, IFN-g down-regulates the expression of ACE2

osine or guanosine nucleosides that then become

on the cell surface and protects type I pneumocytes

incorporated

from SARS-CoV infection (51). The combination of

into

viral

RNA

and

inhibit

RNA-

dependent replication in RNA viruses. Ribavirin is

lopinavir/ritonavir and IFN-b1b is being evaluated

currently FDA-approved for the treatment of chronic

in the treatment of laboratory-conﬁrmed MERS

hepatitis C virus infection in combination with

requiring

peginterferon alfa-2a (Pegasys, Genentech).

evaluated in the SOLIDARITY trial (40).

hospitalization

(52)

and

will also

be

P r o t e a s e i n h i b i t o r s . Lopinavir is a protease inhibi-

A number of additional immunomodulatory agents

tor class that is used in ﬁxed-dose combination with

are also currently being evaluated, including the

another protease inhibitor, ritonavir (lopinavir/rito-

interleukin (IL)-6 inhibitor, tocilizumab, and gluco-

navir [Kaletra, AbbVie Inc., North Chicago, Illinois])

corticosteroids (Tables 4 and 5), given the cytokine

for the treatment of human immunodeﬁciency virus.

storm syndrome that has been observed in subgroups

Results from a randomized, open-label study of 199

with severe COVID-19 (53) with increased levels of

hospitalized adult patients with conﬁrmed SARS-

IL-2, IL-6, IL-7, and additional inﬂammatory cyto-

CoV-2 infection assigned 1:1 to lopinavir 400 mg–

kines (54). One meta-analysis suggested that the

ritonavir 100 mg twice daily for 14 days with stan-

mean IL-6 levels were 2.9-fold (95% CI: 1.17 to

dard of care or standard of care alone were recently

7.19-fold)

published (48). All patients had an oxygen saturation

compared with noncomplicated COVID-19 (54). Toci-

of 94% on room air or a ratio of partial pressure of

lizumab (Actemra, Genentech) is FDA-approved for

oxygen

inspired

the treatment of severe cytokine release syndrome in

oxygen <300 mg Hg. The primary endpoint was time

patients treated with chimeric antigen receptor T-cell

to clinical improvement, where clinical improvement

therapy and is also approved for the treatment of

was deﬁned based on an ordinal scale or survival from

rheumatoid arthritis (55–58). Tocilizumab is a mono-

the hospital. The study was designed for 80% power

clonal antibody that binds the IL-6 receptor, both the

with a 2-sided signiﬁcance level of a of 0.05 to detect

membrane-bound and soluble forms, thus inhibiting

an 8-day difference in median time to clinical

both classic and trans-IL-6 downstream signaling.

improvement. Here, the median time to clinical

Similarly, the IL-6 humanized murine chimeric

improvement was 16.0 days (IQR: 13.0 to 17.0 days) in

monoclonal

the

with

FDA-approved for the treatment of cytokine release

16.0 days (IQR: 15.0 to 18.0 days) with standard care.

syndrome, has also been used in the treatment of

The mortality at 28 days in the treatment group was

cytokine release syndrome and is also being studied

similar to that observed in the standard care group

as a potential therapy in severe COVID-19 infections.

(19.2% vs. 25%; difference: 5.8%; 95% CI: 17.3% to

Siltuximab (Sylvant, Janssen Biotech Inc., Horsham,

5.7%), as was the detectable viral load. However,

Pennsylvania) binds directly to IL-6 and prevents the

there were some suggestions of potential beneﬁt with

activation

lopinavir/ritonavir with a shorter intensive care unit

(Kevzara, Sanoﬁ US, Bridgewater, New Jersey) is a

stay (median: 6 days vs. 11 days) and a shorter time to

human monoclonal antibody against the IL-6 receptor

hospital discharge (median: 12 days vs. 14 days). As

that was developed for the treatment of rheumatoid

noted, the ﬁxed-dose combination of lopinavir/rito-

arthritis that is also being evaluated for severe

navir is 1 treatment arm in the SOLIDARITY trial

COVID-19.

to

the

lopinavir/ritonavir

fraction

group

of

compared

(Table 3) (40).

greater

in

antibody

of

immune

patients

with

siltuximab,

effector

complicated

although

cells.

not

Sarilumab

There are no systematically obtained clinical data

IMMUNOMODULATORY THERAPIES. Interferons (IFNs)

yet that support a beneﬁt to the use of steroids, and

are cytokines that activate the innate immune

some reports have suggested a possible detriment

system in response to viral infection. Type I in-

with delayed viral clearance and increased risk of

terferons (IFN- a /b) are synthesized by most cell

infection with MERS and SARS, although the role of

types in the body response to a viral infection,

steroids in COVID-19 is an area of active investigation

whereas type II interferon (IFN-g ) is produced by

(Table 4) (59).
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COVID-19 AND CARDIOVASCULAR DISEASE

providing care to patients with COVID-19, so that they
can better understand the emerging cardiovascular

The COVID-19 pandemic has presented innumerable

epidemiology of COVID-19, as well as the biological

challenges to health care organizations and health

rationale for the plethora of clinical trials that are

care providers. Given that the vast majority of pa-

either being designed or are currently recruiting

tients with cardiovascular disease are at high risk for

patients.

SARS-CoV-2 infection, the cardiovascular and cardio-
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